Answers are grounded in this paper and cite their sources.
SUMMARY Allogeneic blood transfusion (ABT) has been claimed to cause deleterious clinical effects, including the recurrence of resected malignancies, postoperative bacterial infection, and virus activation. These purported adverse effects of ABT have been attributed to transfusion‐related immunomodulation (TRIM). However, the mechanism(s) of the TRIM effect(s) remains or remain to be defined, and the blood constituent(s) that might mediate TRIM effect(s) is or are unknown. Randomized, controlled trials (RCTs) have been conducted to investigate the TRIM effect(s), based on the assumption that the transfusion of autologous or leukoreduced allogeneic red blood cells is immunologically neutral. The findings of these RCTs have been highly contradictory, and the long‐standing hypothesis of a deleterious TRIM effect of ABT remains unresolved. This review examines the clinical evidence as to whether a deleterious TRIM effect exists and can be abrogated by leukoreducing transfused cellular blood components.
No takes yet. Share an insight, caveat, or question.
Eleftherios C. Vamvakas (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: